Fujifilm Rebrands Life Sciences Units to Strengthen Unified Market Presence Under ‘Partners for Life’ Strategy

Fujifilm Corporation announced today a strategic rebranding of its life sciences companies aimed at unifying its offerings under a single, integrated identity to better serve customers across the full spectrum of drug development. As part of the overhaul, FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, and FUJIFILM Diosynth Biotechnologies rebrands as FUJIFILM Biotechnologies.

The move is part of a broader initiative to align the company's growing life sciences portfolio under the Fujifilm Life Sciences umbrella with a new tagline: “Partners for Life.” This restructuring is intended to streamline customer engagement and reflect Fujifilm’s growing role as an end-to-end provider of solutions for the biopharmaceutical industry—from discovery through to commercial manufacturing.

A Unified Vision Across the Drug Development Lifecycle

“By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector,” said Toshihisa Iida, corporate vice president and general manager of Life Sciences Strategy Headquarters. “Unifying under a single banner simplifies engagement for our global customers and ensures shared strategy and purpose across all our life sciences teams.”

FUJIFILM Biosciences, based in Santa Ana, California, will continue its legacy as a pioneer in cell culture media, building on a 55-year history of innovation. The newly named entity will broaden its scope with a comprehensive portfolio that includes research reagents, recombinant proteins, specialty chemicals, and assay materials. While the new brand takes effect immediately, the legal name change is slated for January 1, 2026.

“We’re excited about this evolution,” said Brandon Pence, president and COO of FUJIFILM Biosciences. “By expanding our capabilities and staying true to our core principles—innovation, service, and people—we aim to deepen our impact in the life sciences community.”

FUJIFILM Biotechnologies, formerly FUJIFILM Diosynth Biotechnologies, remains a top global CDMO (contract development and manufacturing organization), offering development-to-commercialization services for biologics, advanced therapies, and vaccines. The company retains its legal name but will now operate under the new brand identity.

“At FUJIFILM Biotechnologies, we take immense pride in helping bring life-changing medicines to patients,” said Lars Petersen, president and CEO. “This rebrand is about greater coordination and focus—offering our customers scientific rigor, speed, and flexibility.”

A $10 Billion Commitment to Life Sciences

Fujifilm has invested over $10 billion in life sciences over the past 15 years through acquisitions and facility expansions. The company aims to integrate its proprietary technologies—such as AI, imaging, and sensing—with biopharma innovation to drive new value for partners and patients.

Alongside the rebranded entities, the Fujifilm Life Sciences Group includes FUJIFILM Cellular Dynamics, FUJIFILM Wako Pure Chemical Corporation, and FUJIFILM Toyama Chemical Co., Ltd., each contributing specialized capabilities to the unified platform.

Meet Fujifilm Life Sciences at BIO International

The newly rebranded group will showcase its integrated offerings at BIO International Convention 2025 in Boston, June 16–19, at Booths 2334 and 2234.

You can find out more aboit BIO International and other upcoming events on the BioFocus event spotlight page.